

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Zavesca (miglustat)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Zavesca (miglustat) 100mg capsules

APPROVAL CRITERIA

Requests for Zavesca (miglustat) may be approved when the criteria below are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of type 1 Gaucher disease confirmed by either of the following (Wang, 2011; Weinreb, 2004):
 - A. Deficiency in glucocerebrosidase enzyme activity as measured in the white blood cells or skin fibroblasts; **OR**
 - B. Genotype testing indicates mutation of two alleles of the glucocerebrosidase genome;

AND

- III. Individual has clinically significant manifestations of Gaucher disease including (Andersson, 2005; Weinreb, 2004):
 - A. Skeletal disease (including, but not limited to avascular necrosis, Erlenmeyer flask deformity, osteopenia or pathological fracture);**OR**
 - B. Presents with at least two of the following:
 1. Clinically significant splenomegaly; **OR**
 2. Clinically significant hepatomegaly; **OR**
 3. Hemoglobin at least 1.0 g/dL below lower limit for normal for age and sex; **OR**
 4. Platelet count less than or equal to 120,000 mm³

AND

- IV. Enzyme replacement therapy (for example, Cerezyme (imiglucerase), Eleyso (taliglucerase alfa), VPRIV (velaglucerase alfa)) is not a therapeutic option, for reasons such as but not limited to any of the following (Label; Weinreb, 2005):
 - A. Medically unmanageable hypersensitivity; **OR**
 - B. Development of therapy-limiting inhibitory antibodies; **OR**
 - C. Poor peripheral or central venous access.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Continuation requests for Zavesca (miglustat) may be approved if the following criterion is met:

- I. There is confirmation of clinically significant improvement in clinical signs and symptoms of disease (including but not limited to reduction of spleen volume, reduction of liver volume, resolution of anemia, resolution of thrombocytopenia, reduction in fatigue, improvement in skeletal manifestations).

Zavesca (miglustat) may **not** be approved for the following:

- I. Severe type 1 Gaucher disease (hemoglobin less than 9 g/dL, platelet count less than 50,000 mm³, or those at risk of developing new bone complications) (Weinreb, 2005); **OR**
- II. Individual has severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m²); **OR**
- III. Individual has mild, moderate, or severe hepatic impairment or cirrhosis; **OR**
- IV. When given in conjunction with any of the following:
 - A. Cerdelga (eliglustat); **OR**
 - B. Gaucher disease enzyme replacement therapies [Cerezyme (imiglucerase), Eleyso (taliglucerase alfa), or VPRIV (velaglucerase alfa)].

Key References:

1. Andersson HC, Charrow J, Kaplan P, et al., International Collaborative Gaucher Group (ICGG) US Regional Coordinators. Individualization of long term enzyme replacement (ERT) for Gaucher's disease. *Genet Med*. 2005; 7(2):105-110.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 2, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. *Ann Intern Med*. 1995;122:33-39.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
6. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease – Diagnosis and disease management algorithms. *Am J Hematol*. 2011; 86(1):110-115.
7. Turkia HB, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. *Am J Hematol*. 2013; 88(3):179-84.
8. Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuropathic Gaucher disease: revised recommendations. *J Inherit Metab Dis*. 2009; 32(5):660-664.
9. Wang RY, Bodamer OA, Watson MS, Wilcox WR; American College of Medical Genetics (ACMG) Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. *Genet Med*. 2011; 13(5):457-484.
10. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. *Semin Hematol*. 2004; 41(Suppl 5):15-22.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

11. Weinreb NJ, Barranger JA, Charrow J, et. al. Guidance on the use of miglustat for treating patients with Type 1 Gaucher disease. *Am J Hematol.* 2005; 80: 223-229.
12. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. *Blood.* 2011; 118: 5767-5773.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.